#United States #New York #Securities Fraud #Rosen Law Firm #uniQure N.V.

Investors in uniQure N.V. Can Now Participate in Class Action Lawsuit

The Rosen Law Firm, a prominent advocate for investor rights, has officially launched a class action lawsuit on behalf of individuals who purchased ordinary shares of uniQure N.V. (NASDAQ: QURE) during the designated class period, which spans from September 24, 2025, to October 31, 2025. This lawsuit arises from allegations regarding securities fraud and misrepresentation.

What You Need to Know

If you bought shares of uniQure within the specified timeframe, you may be eligible for compensation without incurring any out-of-pocket expenses, thanks to a contingency fee arrangement. Interested investors must act quickly, as the deadline to file as a lead plaintiff is set for April 13, 2026. This is crucial as a lead plaintiff represents the interests of the class in these proceedings.

How to Participate

Joining the uniQure class action is straightforward. Interested individuals can visit the Rosen Law Firm's website to submit a form or reach out directly to Phillip Kim, Esq., via toll-free phone at 866-767-3653 or email at [email protected]. However, it’s important to note that while a class action has been initiated, class certification has not yet occurred, which means that prospective plaintiffs must carefully decide whether to retain counsel or remain passive members of the class.

Why Choose Rosen Law Firm?

The legal team at Rosen Law Firm is recognized for its extensive experience and success in handling securities class actions. The firm has a notable track record, having achieved significant settlements for investors, including the largest securities class action settlement against a Chinese company. Furthermore, by 2017, the firm was recognized as the top firm for securities class action settlements, providing robust advocacy for achieving fair compensation for aggrieved shareholders.

Details of the Allegations

The core of the allegations indicates that defendants misrepresented critical information or failed to disclose key facts regarding uniQure's pivotal study for its leading drug candidate aimed at treating Huntington's Disease. Specifically, these misrepresentations include:
1. The lack of full approval from the U.S. Food and Drug Administration (FDA) for the design of the pivotal study, which compared the study's outcomes to external historical data.
2. Underestimating the potential delays in the timeline for the Biologics License Application (BLA) submission due to the necessity for additional studies.
3. Stating that the company's claims regarding operations, business development, and market prospects were baseless.

When these essential details became publicly available, it led to significant damages for investors who were misled.

Conclusion

If you were a shareholder of uniQure during the specified period, the ongoing class action presents a pivotal opportunity for potential compensation. Ensuring that knowledgeable legal representation is chosen will be critical in navigating this complex process. For ongoing updates regarding the lawsuit, interested parties should follow the Rosen Law Firm on various social media platforms including LinkedIn, Twitter, and Facebook.

The Rosen Law Firm emphasizes that prior case outcomes do not guarantee similar results in current or future cases. This initiative represents not just a legal pursuit, but a stand for justice and accountability in the investment community as a whole.